Avacta Archives

News and Trends 8 Mar 2023

How to get started in life sciences – tips from six top women biotech leaders

The life sciences industry might seem like an attractive sector for women to start their career and find a job. But just how should women get started in the sector? We asked six top professionals in the field for their advice. We asked Charli Batley, COO, Phoremost; Tamsin Mansley, president, Optibrium Inc. and global head […]

March 8, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 8 Mar 2023

Women in STEM: challenges and opportunities

In this article to celebrate International Women’s Day, we asked women in STEM for their comments on the challenges they have faced in their careers so far, and how solutions can emerge from these challenges. We get advice from Fiona McLaughlin, CSO, Avacta Therapeutics; Maureen Coleman, chairman, CN Bio; Debora Lucarelli, CEO, Enhanc3D Genomics; Tamsin […]

March 8, 2023 - 14 minutesmins - By Jim Cornall

News and Trends 8 Mar 2023

How to encourage more women in life science jobs

In this article to celebrate International Women’s Day, we asked six women biotech professionals for their observations on women in the life sciences industry. We spoke to Sheelagh Frame, CSO, Ubiquigent; Debora Lucarelli, CEO, Enhanc3D Genomics; Charli Batley, COO, Phoremost; Tamsin Mansley, president, Optibrium Inc. and global head of application science, Optibrium; Maureen Coleman, chairman, […]

March 8, 2023 - 8 minutesmins - By Jim Cornall

circulating tumor cells, cancer, clinical trials

News and Trends 19 Jan 2023

Avacta completes fourth dose escalation in tumor study

Avacta Group plc says that AVA6000 continues to show a favorable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. Additionally, analysis of tumor biopsies obtained from six patients across several cohorts indicates that doxorubicin is being released within the tumor tissue. This confirms the tumor targeting potential […]

January 19, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

Avacta’s drug targeting soft tissue sarcoma granted Orphan Drug Designation by FDA

A drug to treat soft tissue sarcoma has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). Clinical stage oncology drug company Avacta Group plc has produced a form of the generic chemotherapy, doxorubicin AVA6000. About Avacta’s drug The drug has been modified using the company’s pre|CISION technology and Affirmer […]

September 5, 2022 - 2 minutesmins - By Liza Laws

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Avacta

How to get started in life sciences – tips from six top women biotech leaders

Women in STEM: challenges and opportunities

How to encourage more women in life science jobs

Avacta completes fourth dose escalation in tumor study

Avacta’s drug targeting soft tissue sarcoma granted Orphan Drug Designation by FDA

Subscribe to our newsletter to get the latest biotech news!